1-6 of 6
Giles Best, BSc, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TR57, an Inhibitor of the Integrated Stress Response, Is Synergistic with Venetoclax Against CLL Cells, Independent of Their TP53 Status

Narjis Fatima, BSMedTech,MPhil, Yandong Shen, BMedSc (Hon) PhD, Kyle R Crassini, MBBS,BSc, Edwin Iwanowicz, PhD, Richard Christopherson, PhDEmeritus Professor, Giles Best, BSc, PhD, Stephen P. Mulligan, PhDFRACP,FRCPA,MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 1735.
https://doi.org/10.1182/blood-2019-132160
Published: 2019
Journal Articles

Detailed Long-Term Follow up of Treatment-Naive Chronic Lymphocytic Leukemia (CLL) Patients in the Australasian Leukemia and Lymphoma Group (ALLG) CLL5 Trial; Data on 17 (15% of Total Cohort) Patients from a Single-Institution

Suneet Sandhu, MBBS, MPH, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Luke Coyle, MBBS, FRACP, FRCPA, Giles Best, BSc, PhD, Stephen Mulligan, MBBS, PhD FRACP, FRCPA
Journal: Blood
Blood (2015) 126 (23): 5294.
https://doi.org/10.1182/blood.V126.23.5294.5294
Published: 2015
Journal Articles

Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial

Suneet Sandhu, MBBS, MPH, FRACP, FRCPA, Devinder Gill, MB FRCPath FRACP FRCPA, Paul David Turner, MBBS, FRACP, FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Leanne Berkahn, MD, David R Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Cecily Forsyth, MBBS, FRACP, FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Rosemary Harrup, MBBS, FRACP, FRCPA, Giles Best, BSc, PhD, Mathias Bressel, MSc, Juliana Di Iulio, BAppSc, PhD, Bryone Jean Kuss, PhD MBBS, FRCPA, FRACP, Stephen Mulligan, MBBS, PhD FRACP, FRCPA
Journal: Blood
Blood (2015) 126 (23): 5295.
https://doi.org/10.1182/blood.V126.23.5295.5295
Published: 2015
Journal Articles

MAPK-Erk1/2 Pathway Activation and Survival Of Chronic Lymphocytic Leukemia (CLL) Cells Is Induced By In Vitro Modeling Of The Tumor Microenvironment and Can Be Effectively Inhibited Using The MEK1 Inhibitor MEK162

O. Giles Best, BSc, PhD, Kyle Crassini, William s Stevenson, MBBS, PhD, Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA
Journal: Blood
Blood (2013) 122 (21): 4192.
https://doi.org/10.1182/blood.V122.21.4192.4192
Published: 2013
Journal Articles

The Hsp90 Inhibitor SNX7081 Restores the Fludarabine Sensitivity of Chronic Lymphocytic Leukemia (CLL) Cells Harbouring Mutations of ATM or TP53

O. Giles Best, BSc, PhD, Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA
Journal: Blood
Blood (2010) 116 (21): 2473.
https://doi.org/10.1182/blood.V116.21.2473.2473
Published: 2010
Journal Articles

The Safety and Tolerability of Oral Fludarabine, ±oral Cyclophosphamide and Iv Rituximab Therapy In Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – Interim Analysis From the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study.

Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA, Devinder S Gill, MD, William E. P. Renwick, MBBS, FRACP, Melanie L Sulda, BSc, Ph.D, O. Giles Best, BSc, PhD, Bryone J Kuss, PhD, FRCPA, FRACP, MBBS, John F Seymour, MD, FRACP
Journal: Blood
Blood (2010) 116 (21): 699.
https://doi.org/10.1182/blood.V116.21.699.699
Published: 2010